Shots:

• Vyriad to receive upfront- development and commercial milestone payments based on certain achievements and royalties on sales of products. Regeneron to get an exclusive option to license Vyriad's Voyager-V1 plus other products and will make equity investment in Vyriad
• The agreement also includes a P-II clinical study assessing Regeneron's Libtayo (cemiplimab-rwlc) + Vyriad's oncolytic virus Voyager-V1 in multiple types of cancer- including melanoma- lung- liver and endometrial cancers. Additionally- the companies will enter into a five-year research collaboration to design and develop Vesicular Stomatitis Virus (VSV)-based oncolytic virus therapies utilizing Regeneron's VelociSuite technologies
• Voyager-V1 is an oncolytic virus designed to enhance safety- efficacy- and traceability with the inclusion of interferon-beta gene and is also being evaluated in P-I/II study for mCRC- endometrial cancer- NSCLC- SCC of the head and neck and various blood cancers. Regeneron’s Libtayo is a mAb targeting immune checkpoint receptor PD-1 developed in collaboration with Sanofi

Click here to­ read full press release/ article | Ref: PRNewswire | Image: Behance